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Abstract
Background
The impact of high platelet reactivity (HPR) on clinical outcomes after elective percutaneous
coronary interventions (PCI) with drug-eluting balloons (DEB) due to in-stent restenosis
(ISR) is unknown.
Objective
We sought to evaluate the prognostic importance of HPR together with conventional risk
factors in patients treated with DEB.
Methods
Patients treated with DEB due to ISR were enrolled in a single-centre, prospective registry
between October 2009 and March 2015. Only patients with recent myocardial infarction (MI)
received prasugrel, others were treated with clopidogrel. HPR was defined as an ADP-test
>46U with the Multiplate assay and no adjustments were done based on results. The pri-
mary endpoint of the study was a composite of cardiovascular mortality, MI, any revasculari-
zation or stroke during one-year follow-up.
Results
194 stable angina patients were recruited of whom 90% were treated with clopidogrel. Clini-
cal characteristics and procedural data were available for all patients; while platelet function
testing was performed in 152 subjects of whom 32 (21%) had HPR. Patients with HPR had
a higher risk for the primary endpoint (HR: 2.45; CI: 1.01–5.92; p = 0.03). The difference
was primarily driven by a higher risk for revascularization and MI. According to the multivari-
ate analysis, HPR remained a significant, independent predictor of the primary endpoint
(HR: 2.88; CI: 1.02–8.14; p = 0.04), while total DEB length and statin treatment were other
independent correlates of the primary outcome.
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Conclusion
HPR was found to be an independent predictor of repeat revascularization and MI among
elective patients with ISR undergoing PCI with DEB.
Introduction
Coronary in-stent restenosis (ISR) is a common complication with bare metal stents and is
still a limitation of concern with current-generation drug-eluting stents.[1] In the last few
years, drug-eluting balloon (DEB) dilatation has emerged as a therapeutic alternative to drug
eluting stent (DES) implantation for percutaneous treatment of ISR. DEB may offer a benefit
to treat ISR without repeat implantation of a metal layer into the restenotic mass, that itself,
with the polymer on its surface is a key driver of the adverse process. [2] Several randomized
studies have demonstrated the safety and efficacy of this technology. [3] [4] Moreover, a meta-
analysis including more than 1400 patients demonstrated that DEB was clinically non-inferior
to DES in the treatment of ISR in different clinical scenarios. [2]
After DEB percutaneous coronary intervention (PCI), patients receive double antiplatelet
therapy (DAPT) for a certain timeframe but the optimal intensity and duration is not clearly
defined. High residual platelet reactivity (HPR) in patients on clopidogrel has been demon-
strated to be a strong and independent predictor of recurrent ischemic events and mortality in
patients after coronary stent implantation. [5]
However, the relevance of HPR in the setting of ISR and DEB dilation is unknown. A prior
study with optical coherence tomography (OCT) demonstrated uncovered or malapposed
stent struts and intimal dissections in DEB-dilated segments [6] that may provide a prothrom-
botic surface after balloon dilation. As healing may be delayed consequent to paclitaxel treat-
ment, this may have potential implications regarding the efficacy of antiplatelet therapy. The
objective of our study was to evaluate the impact of HPR together with patient-related and pro-
cedural characteristics on clinical outcomes in patients with ISR treated with DEB.
Methods
Population
Starting on October 1, 2009, patients treated with DEB for ISR were enrolled in a single centre
prospective registry in the Heart Institute, University of Pe´cs. There were no exclusion criteria;
this was an all-comer registry. The registry adhered to the tenets of the most recent revision of
the Declaration of Helsinki. The institutional ethical board (Regional Research Ethics Com-
mittee, University of Pe´cs, Clinical Centre) reviewed the protocol and approved this study
under the protocol number 3551/2009. All included subjects have been properly instructed
and have given written informed consent.
Registered data
Data were collected prospectively from dedicated hospital records. Follow-up data were
obtained at clinical presentations and at a telephone visit scheduled at 12 months after the
index DEB PCI. Detailed procedural parameters of the intervention as well as risk factors,
demographic data, medication information and laboratory parameters were also registered
(Table 1).
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Table 1. Baseline characteristics of the patient population.
Baseline characteristics Entire patient population (n = 194) HPR (n = 32) no HPR (n = 120) p¶
Clinical characteristics
• Age 59.7 (31.4–85.7) 57.7 (37.9–72.2) 59.6 (31.4–85.7) 0.15
• Male 118 (60.6) 23 (71.9) 67 (55.8) 0.11
• Smoking 47 (24.1) 10 (31.3) 25 (20.8) 0.24
• Hypertension 173 (88.7) 27 (84.4) 112 (93.3) 0.14
• Diabetes mellitus 48 (24.6) 11 (34.4) 29 (24.2) 0.26
• Statin treatment (dyslipidaemia) 95 (48.7) 15 (46.9) 60 (50.0) 0.84
• Prior MI 135 (69.2) 23 (71.9) 85 (70.8) 1.00
• Prior CABG 36 (18.5) 3 (9.4) 26 (21.7) 0.14
• High platelet reactivity 32 (16.4)
Prior PCI procedure
• Indication 0.93
• STEMI 63 (32.5) 11 (34.4) 36 (30.0)
• NSTEMI 17 (8.8) 3 (9.4) 9 (7.5)
• Unstable angina 26 (13.4) 5 (15.7) 19 (15.8)
• Stable angina 82 (42.3) 12 (37.5) 51 (42.5)
• Target vessel 0.14
• LAD 76 (39.2) 10 (31.3) 51 (42.5)
• RCA 86 (44.3) 20 (62.5) 50 (41.7)
• CX 24 (12.4) 2 (6.3) 12 (10.0)
• Graft 8 (4.1) 0 (0.0) 7 (5.8)
• Total stent length, mm 30 (8–138) 31 (13–101) 30 (8–138) 0.88
• Stent count/patient 2 (1–7) 2 (1–5) 2 (1–7) 0.64
• Drug eluting stent 51 (26.2) 4 (12.5) 37(30.8) 0.04
DEB procedure
• Type of DEB 0.04
• SeQuent Please 58 (29.9) 4 (12.5) 43 (35.8)
• Invatec In-Pact. 70 (36.1) 16 (50.0) 45 (37.5)
• Protege 39 (20.1) 10 (31.3) 22 (18.3)
• Pantera Lux 24 (12.4) 1 (3.1) 9 (7.5)
• Total DEB length, mm 25.5 (12–90) 23 (12–60) 20 (12–60) 0.78
• Total DEB length 22.5, mm 103 (52.8) 16 (50.0) 59 (49.2) 1.00
• Largest DEB diameter, mm 3 (2.5–5) 3.5 (2.5–4) 3 (2.5–5) 0.19
• DEB count/patient 1 (1–4) 1 (1–2) 1 (1–2) 0.71
• Predilatation 169 (86.7) 28 (87.5) 107 (89.2) 0.75
• ADP-test, U 28 (2–91)
• ADP-test 52.5, U 23 (11.8)
• ADP-test 63.5, U 15 (7.7)
• Type 4 MI troponin 13 (6.7) 4 (12.5) 6 (5.0) 0.21
• Complication 31 (15.9) 6 (18.8) 22 (18.3) 1.00
Laboratory findings
• Red blood cell distribution width 15.2 ± 1.9 14.3 (13.6–18.2) 15.1 (12.5–17.1) 0.77
• Leukocyte count, g/l 7.9 (4.5–13.7) 8.5 ± 3.0 8.5 ± 1.9 0.98
• Platelet count, g/l 251 ± 60 286.8 ± 83.5 248.7 ± 57.2 0.33
• Mean platelet volume 8.7 ± 1.1 8.3 ± 1.2 8.8 ± 1.1 0.33
• C-reactive protein, mg/l 2.2 (0.6–23.6) 12.1 ± 11.0 2.2 ± 1.6 0.26
Discharge medication
(Continued )
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Percutaneous coronary intervention and antiplatelet therapy
The selection of technique and revascularization strategy was at the discretion of the operators,
including the choice of vascular access, type and number of DEB and need for pre- or post-
dilatation or bailout stenting. Antiplatelet treatment was given according to the actual Euro-
pean guidelines of myocardial revascularization and treatment of stable angina.[7] All patients
received 100 mg of aspirin, and clopidogrel was the choice from oral P2Y12-inhibitors. Only a
small group of patients with prior acute myocardial infarction (AMI) within a year were
treated with prasugrel that was continued regardless of the platelet function testing. Patients
on clopidogrel continued treatment with an optional loading dose at the time of PCI decided
by the operator. Patients without chronic P2Y12-inhibitors were treated with a 300/600 mg
loading dose of clopidogrel, followed by a maintenance dose of 75 mg/day. Dual antiplatelet
therapy was proposed to maintain during 12 months after DEB PCI.
Platelet function testing
Antecubital venous blood samples were collected using a sterile 21-gauge needle into hirudin
coated vacuum tubes (Becton and Dickinson, Munich, Germany) without stasis. Platelet func-
tion testing was performed with the Multiplate analyser (Roche Diagnostics, Rotkreuz, Swit-
zerland), at least 6 hours after PCI. HPR was defined according to the consensus cut-off, which
was an adenosine diphosphate (ADP)-test value greater than 46 U. [8] Importantly, results of
platelet function testing did not lead to treatment corrections regarding P2Y12-inhibitor
treatment.
Endpoints and follow-up
Patients were followed for one year after DEB intervention. The primary endpoint of the study
was the occurrence of major adverse cardiac events (MACE) defined as the composite of car-
diovascular (CV) mortality, any revascularization, myocardial infarction (MI) or stroke/
Table 1. (Continued)
Baseline characteristics Entire patient population (n = 194) HPR (n = 32) no HPR (n = 120) p¶
• Clopidogrel 175 (90.2) 25 (78.1) 111(92.5) 0.04
• Prasugrel 17 (8.8)† 7 (21.9) 8 (6.7) 0.02
• ACE-I 139 (71.3) 23 (71.9) 84 (70.0) 1.00
• ARB 39 (20.0) 9 (28.1) 23 (19.2) 0.32
• Beta-blocker 155 (79.5) 25 (78.1) 96 (80.0) 0.81
• Calcium channel blocker 65 (33.3) 11 (34.4) 40 (33.3) 1.00
• Allopurinol 17 (8.7) 0 (0) 9 (7.5) 0.21
• PPI 158 (81.0) 28 (87.5) 95 (79.2) 0.45
• Antacid 37 (18.9) 5 (15.6) 25 (20.8) 0.62
Values are mean ± SD, n (%), or median (interquartile range).
¶ Comparison between HPR vs. no HPR patients.
† 2 (1%) patients received ticlopidine therapy.
HPR = high platelet reactivity; MI = myocardial infarction; CABG = coronary artery bypass graft; PCI = percutaneous coronary intervention; STEMI = ST-
segment elevation myocardial infarction; NSTEMI = non–ST-segment elevation myocardial infarction; LAD = left anterior descending; RCA = right coronary
artery; Cx = circumflex artery; DEB = drug eluting balloon; ADP = adenosine diphosphate; ACE-I = angiotensin-converting enzyme inhibitor;
ARB = angiotensin receptor blocker; PPI = proton pump inhibitor
https://doi.org/10.1371/journal.pone.0188493.t001
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transient ischemic attack (TIA). Secondary endpoints included the individual elements of the
composite endpoint.
Any revascularization included percutaneous or surgical interventions of the coronary
arteries after the DEB PCI. MI was defined according to the universal definition.[9] Type 4
periprocedural MI was not considered as an endpoint. Stroke and TIA was defined according
to American Heart Association/American Stroke Association definition.[10] [11]
Statistical analysis
Continuous variables with normal distribution are presented as mean ± standard deviation
(SD), whereas non-normally distributed variables are presented as median and interquartile
range. Categorical variables are expressed as frequencies and percentages. Differences between
groups were assessed with the Fisher’s exact test or chi-square test, as appropriate for categori-
cal variables. Unpaired t tests were used for comparisons of normally distributed continuous
variables, whereas non-normally distributed variables were compared using the Mann-Whit-
ney U test. Hazard ratios (HR) and 95% confidence intervals (CI) were calculated for occur-
rence of clinical endpoints at follow-up. Cox regression and Kaplan-Meier analysis was
performed to assess the impact of demographic, clinical and procedural characteristics on the
study’s endpoint. Variables were assessed in univariate as well as in multivariate Cox propor-
tional model analyses. In the latter, covariates with a threshold of p< 0.10 in the univariate
Cox analyses were entered into an initial multivariate model than removed stepwise based on
the probability of the likelihood-ratio statistic to determine independent predictors of the clin-
ical endpoint. Improvement over the baseline model was checked with Omnibus tests of
model coefficients.
Survival differences between the groups and the cumulative incidence of the clinical end-
point were calculated according to the Kaplan-Meier method. Specificity and sensitivity of
platelet function test cut-off points in predicting the occurrence of the primary endpoint were
determined by ROC curve analysis. Values of p<0.05 were considered statistically significant
and values of p<0.1 were considered as a trend.
Statistical analysis was performed using SPSS Statistics V22 (IBM Corporation, Armonk,
NY, USA) and Graph Pad Prism software 5 (GraphPad Software, Inc., La Jolla, CA, USA).
Results
Clinical characteristics
Between October 1, 2009 and March 31, 2015, 194 patients (60.6% male) were enrolled in the
registry with a median age of 60 (range: 31–86) years. All of the recruited cases were treated
during an elective DEB intervention due to stable angina. No patients were lost to follow up.
The mean follow-up time was one year. Baseline clinical, procedural, laboratory and treatment
characteristics are shown in Table 1.
Based on their cardiovascular risk factors, study patients composed a low-to-moderate risk
cohort with 89% hypertension, 49% dyslipidaemia and 25% diabetes. Sixty-nine percent of the
patients had previous MI and 19% of them had previous coronary artery bypass grafting
(CABG). The vast majority of the patients were treated with clopidogrel (90%) while 9%
received prasugrel and 1% of the patients received ticlopidine therapy.
Regarding procedural data, 26% of the ISR cases were found in a previously implanted
DES. Eighty-seven percent of the cases underwent predilatation prior to the use of DEBs.
Overall, 152 (78%) patients had ADP-test available after DEB PCI. The reasons for omission
of the ADP test were logistic reasons, transfer or discharge of the patient without blood sam-
pling in 14% or unavailable lab on the day after the PCI in 8%. Patients with and without
Platelet reactivity in DEB-treated patients with ISR
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ADP-test available had comparable baseline characteristics except for greater use of allopurinol
in those who did not present ADP-test. The median value of the ADP-test after DEB PCI was
28 U.
From the 152 subjects tested, 32 (21%) had HPR according to Multiplate assay. There was a
significant difference in the frequency of DES and bare metal stent (BMS) -use by the prior
PCI between HPR and no HPR groups; with significantly more DES ISR in the HPR group. In
addition, the choice of DEB differed among the groups with or without HPR; however, these
parameters did not have an effect on the composite clinical endpoint.
Clinical outcomes
Thirteen (6.7%) patients had elevated troponin level after the procedure defined according to
the universal definition of MI type 4 after the DEB PCI,[9] and other complications occurred
in 31 cases (coronary dissection and perforation, no flow) during the DEB PCI (Table 1).
Twenty-seven patients reached the composite endpoint during the follow-up period. One
patient died due to cardiovascular cause, 12 patients suffered MI during follow-up. Twenty-six
patients had a revascularization event, out of that 17 were target vessel revascularisation
(TVR). There were no documented cases of stroke (Table 2).
The rate of the composite clinical endpoint, revascularization and MI were significantly
higher in the HPR group compared to patients without HPR ([MACE: HR: 2.5; CI: 1.0–5.9;
p = 0.03]; [Revascularisation: HR: 2.5; CI: 1.0–5.9; p = 0.03]; [MI: HR: 3.9; CI: 1.3–12.2;
p = 0.01]). Compared with no HPR patients, HPR group showed a non-significant trend for
higher rate of TVR (HR: 2.8; CI: 0.9–8.8; p = 0.06) (Table 2).
Predictors of ischemic events
According to the Cox regression analyses HPR (HR: 2.45; CI: 1.01–5.92; p = 0.03) (Fig 1A),
and prasugrel therapy (HR: 2.74; CI: 1.04–7.26; p = 0.03) were significant predictors of the pri-
mary endpoint and only patients with recent myocardial infarction received prasugrel at the
time of the DEB procedure.
ROC curve analysis identified two potential cut-off values 52.5 U (33% sensitivity, 12%
specificity) and 63.5 U (28% sensitivity, 7% specificity) of the platelet function test. Using these
and the consensus defined 46 U (38% sensitivity, 12% specificity), Kaplan-Meier analyses dem-
onstrated similarly significant higher risk of composite endpoint ([46 U (HPR): HR: 2.42; CI:
1.01–5.92; p = 0.03]; [52.5 U: HR: 3.09; CI: 1.24–7.67; p = 0.01]; [63.5 U: HR: 4.25; CI: 1.64–
10.96; p = 0.001]) with higher risk but smaller at risk population with the higher cut-off values
(Fig 1A, 1B and 1C; Fig 2). Based on the Kaplan Meier curve morphology and separation, the
Table 2. Clinical outcomes in the patient population and stratified according to the platelet reactivity.
Clinical endpoints Patient population (n = 194) no HPR (n = 120) HPR (n = 32) HR (95% CI) p
Composite endpoint 27 (13.9) 13 (10.8) 8 (25.0) 2.5 (1.0–5.9) 0.03
Any revascularization 26 (13.3) 13 (10.8) 8 (25.0) 2.5 (1.0–5.9) 0.03
TVR 17 (8.7) 7(5.8) 5 (15.6) 2.8 (0.9–8.8) 0.06
MI 12 (6.2) 6 (5.0) 6 (18.8) 3.9 (1.3–12.2) 0.01
CV death 1 (0.5) 0 (0.0) 0 (0.0) - -
TIA/stroke 0 (0.0) 0 (0.0) 0 (0.0) - -
Values are n (%).
HPR = high platelet reactivity; HR = hazard ratio; CI = confidence interval; TVR = target vessel revascularization; MI = myocardial infarction;
CV = cardiovascular; TIA = transient ischaemic attack
https://doi.org/10.1371/journal.pone.0188493.t002
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consensus cut-off value predicts the risk of later (>60 days) events, whereas, the higher cut-off
values are rather predictors for the earlier cardiovascular events (Fig 1A, 1B and 1C).
Furthermore, we found a tendency of poorer outcomes associated with the total length of
the DEB (HR 1.02; CI: 0.99–1.05; p = 0.06).
In order to clarify the role of platelet function testing related to other covariates of the pri-
mary endpoint multivariate models were generated to identify independent predictors.
According to the multivariate analysis, HPR and the efficacy of ADP receptor antagonist
treatment as assessed by the platelet function test remained significant, independent predictor
of the primary endpoint ([HPR: HR: 2.88; CI: 1.02–8.14; p = 0.04]; [ADP test, U: HR: 1.03; CI:
1.00–1.05; p = 0.04]) (Table 3). In the multivariate analysis, history of statin treatment and the
total length of the DEB were significant, independent predictor of the MACE ([statin: HR:
0.28; CI: 0.09–0.84; p = 0.02]; [total DEB length: HR: 1.04; CI: 1.00–1.08; p = 0.03]) (Table 3).
Discussion
The main finding of our study is that HPR may be a predictor of adverse ischemic events in
stable angina patients treated with DEB due to ISR. The higher rate of ischemic events was pre-
dominantly triggered by a higher risk for MI and repeat revascularization. In addition to HPR,
total DEB length and statin treatment were shown to significantly interfere with clinical
outcomes.
Several randomized studies demonstrated the safety and efficacy of DEB for the treatment
of ISR.[3] [4] Based on the results of the PACCOCATH ISR [12] [3] and PEPCAD II [13]
Fig 1. Event free survival of the patients based on the platelet reactivity during the follow up period.
A: Event free survival of the patients with and without HPR based on the consensus cut-off value. B, C: Event
free survival of the patients based on the ROC curve analysis identified two potential cut-off values. Event
rates at one year are shown for each group as Kaplan-Meier estimates. HPR = high platelet reactivity;
ADP = adenosine diphosphate.
https://doi.org/10.1371/journal.pone.0188493.g001
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trials, the European Society of Cardiology/European Association for Cardio-Thoracic Surgery
guidelines for coronary revascularization gave a class IIa recommendation for this treatment
modality.[4] Previous registries and studies investigated the correlation between patient and
procedural characteristics and clinical outcome with heterogeneous results. Our cohort com-
prised a routine all-comer population with low-to-moderate risk clinical and procedural fea-
tures. The incidence of the composite end point was 14% during the 1-year follow-up period,
higher than in randomized trials (9% in PACCOCATH ISR I and II and in PEPCAD II),[3]
[13] but similar to a multicentre prospective registry.[14] Regarding to procedural characteris-
tics, DEB length was found to be an important predictor of adverse outcomes: the longer the
DEB, the higher the risk of ischemic events. Although the length of DEB should be selected to
fully cover the restenotic segment, operators should find the shortest appropriate size, without
large mismatch.
After DEB PCI, patients receive dual antiplatelet therapy but the optimal intensity and
length of the therapy in this patient group is not fully defined. Clopidogrel non-responsiveness
and HPR is a strong independent predictor of recurrent ischemic events and mortality after
coronary stent implantation [5] and may play a relevant prognostic role in patients after DEB
PCI. This association is strongest in patients with ACS, likewise, more potent P2Y12-inhibitors
are used to prevent thrombotic recurrences.[15]
Earlier OCT examination discovered uncovered or malapposed stent struts immediately
after the DEB procedure and in all images dissections were seen throughout the DEB-dilated
segment which were not visible with angiography and remained untreated.[6] Therefore,
although DEB PCI was shown to be an effective treatment for ISR, it may result in a large pro-
thrombotic surface with delayed healing consequent to the paclitaxel treatment. This repre-
sents a potential risk and may necessitate effective antiplatelet therapy to prevent adverse
events.
Fig 2. Results of the platelet function test, frequency of high platelet reactivity and its relation to
clinical endpoints. A: A scatter plot of platelet reactivity with the Multiplate device in all patients. Values are
presented as median {25% percentile, 75% percentile}, ADP reactivity presents as U. B: Percent of the
platelet function tested cases with percent of HPR and no HPR patients in the total cohort based on the
platelet reactivity values. C: Impact of platelet reactivity on MACE. D: Impact of platelet reactivity on MI.
Values are presented as HR [95% CI]. *: asterisk marks hazard ratios from multivariate Cox regression
analyses. ADP = adenosine diphosphate; AUC = area under the curve; HPR = high platelet reactivity;
MACE = major adverse cardiovascular event; MI = myocardial infarction; HR = hazard ratio; CI = confidence
interval.
https://doi.org/10.1371/journal.pone.0188493.g002
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In line with the intraluminal imaging findings, we found a significant association between
platelet reactivity and adverse outcomes and patients with HPR had a 2.5-fold higher risk for
ischemic events. The higher risk was mainly driven by MI and revascularization, while stent
thrombosis (ST) and mortality were rare.
This is in line with earlier randomized trials and a multicentre registry showing a low rate
of early thrombosis of the DEB treated stented segment. [14] [16] [17] In our study, there was
only one diagnosed ST (0.5%) after 4 days of the procedure, in a patient with HPR.
In patients with HPR most of the repeated revascularisations were triggered by events of
acute MI (75% of revascularisation and 80% of TVR), whereas, in patients without HPR 46%
of revascularisations and 57% of TVR were performed because of an acute MI. In-stent reste-
nosis can frequently present as MI [18][19][20] and angiographically, patients with MI tend to
Table 3. Clinical and procedural predictors of MACE at one year.
Univariate Cox Proportional Hazard Model Multivariate Cox Proportional Hazard Model
HR (95% CI) p-value HR (95% CI) p-value
Age 0.98 (0.95–1.02) 0.56
Male gender 1.28 (0.57–2.86) 0.53
Smoking 1.07 (0.44–2.61) 0.87
Hypertension 2.08 (0.28–15.40) 0.46
Diabetes mellitus 0.90 (0.36–2.26) 0.83
Statin treatment 0.49 (0.20–1.17) 0.10 0.28 (0.09–0.84) 0.02
Prior MI 2.20 (0.75–6.41) 0.13
Prior CABG 1.03 (0.39–2.76) 0.94
Indication of prior PCI
• STEMI 1.52 (0.69–3.35) 0.29
• NSTEMI 0.41 (0.05–3.04) 0.36
• Unstable angina 0.84 (0.25–2.82) 0.78
• Stable angina 0.88 (0.39–1.97) 0.77
Target vessel
• LAD 0.62 (0.27–1.43) 0.26
• RCA 1.67 (0.78–3.57) 0.18
• CX 1.20 (0.41–3.47) 0.73
• Graft 0.04 (0.00–160.28) 0.26
Drug eluting stent restenosis 0.76 (0.30–1.88) 0.55
Type of DEB
• SeQuent Please 0.63 (0.25–1.58) 0.32
• Invatec In-Pact 1.39 (0.65–2.97) 0.39
• Protege 1.42 (0.60–3.37) 0.41
• Pantera Lux 0.54 (0.12–2.28) 0.39
Total DEB length, mm 1.02 (0.99–1.05) 0.06 1.04 (1.00–1.08) 0.03
Largest DEB diameter, mm 1.01 (0.44–2.32) 0.97
DEB count/patient 1.52 (0.75–3.05) 0.24
Predilatation 1.24 (0.37–4.12) 0.72
ADP-test, U 1.02 (0.99–1.04) 0.06 1.03 (1.00–1.05) 0.04
Prasugrel treatment 2.74 (1.04–7.26) 0.03
HR = hazard ratio; CI = confidence interval; MI = myocardial infarction; CABG = coronary artery bypass graft; PCI = percutaneous coronary intervention;
STEMI = ST-segment elevation myocardial infarction; NSTEMI = non–ST-segment elevation myocardial infarction; LAD = left anterior descending;
RCA = right coronary artery; Cx = circumflexus; DEB = drug eluting balloon; ADP = adenosine diphosphate; MACE = major adverse cardiovascular event
https://doi.org/10.1371/journal.pone.0188493.t003
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have an aggressive pattern of restenosis and total occlusion of the target lesion. One of the
most likely explanation of MI in ISR include late stent or device thrombosis, which can be
caused by incomplete neointimal coverage, early termination of antiplatelet therapy and/or
increased neointimal thrombogenic tissue factors such as tissue factor and collagen.[18] The
average time between the DEB procedure and the appearance of adverse events was 6 months
(mean 181 days) in our study. When assessed with OCT at 6 months >94%, therefore almost
complete neointimal coverage was found after stent implantation postdilated with DEB [21].
Based on these findings, incomplete neointimal coverage may play a less important role in the
mechanisms of late ischemic events also but supports the relevant role and importance of inef-
fective antiplatelet therapy and residual platelet reactivity in the mechanisms of late ST and
occurrence of repeated MI.
As a consequence of paucity of relevant data corrective treatment in terms of intensification
of antiplatelet therapy based on platelet function studies is not established. Currently available
large scale, randomized trials showed the prognostic role of HPR in patients underwent coro-
nary stent implantation but failed to demonstrate the clinical improvements when treatment
modifications were implemented on the basis of platelet function testing in patients with elec-
tive PCI.[22] [23] [24] [25] The TRIGGER-PCI trial testing switching from clopidogrel to pra-
sugrel in patients with HPR found the 6-month event rate after DES implantation extremely
low and the study stopped prematurely due to futility. [23] In two further trials, in the GRAVI-
TAS and ARCTIC trials, treatment modification that mainly consisted use of high-dose clopi-
dogrel in patients with high platelet reactivity after elective PCI with DES did not reduce the
rate of end points compared with standard therapy.[22] [24] Using different primary end-
point definition, we found a 14% event rate in our real-life cohort and a significantly greater
rate of the composite end-point in patients with HPR compared to patients without HPR (25%
vs 11%) after PCI with DEB while there were no significant differences in clinical, laboratory
and treatment parameters between the HPR and NPR group. Patients treated with prasugrel
because of an acute coronary event within one year had worse outcome in our study. As this
difference persisted in multivariate analyses taking antiplatelet efficacy in account we hypothe-
size that this worse prognosis is rather explainable with the recent ACS than with the antiplate-
let therapy itself. Furthermore, due to the low numbers and lack of randomized comparisons
and protocolled treatment modification our data do not allow drawing conclusion regarding
the efficacy of corrective treatment. According to the multivariate analysis, beside platelet reac-
tivity, history of statin treatment and the total length of the DEB were significant, independent
predictors of the cardiovascular events. The other clinical and procedural characteristics had
no important influence on the outcomes. This finding is in contrast with the earlier published
registry from Cale´ et al. In their analysis of 156 patients the predictors of poorer outcome were
previous MI and CABG, acute coronary syndrome at presentation, and PCI in the LAD, while
DEB length and dyslipidaemia were not predictive of one-year outcome.[14] In our study,
only elective DEB treated ISR patients were recruited which cohort is dissimilar to the popula-
tions of Cale´ et al. with acute coronary syndrome and small vessel disease included which may
explain the differences in the verified determinants of worse results.
Our analyses of the predictive value of different level residual platelet reactivity identified
two potential alternative cut-off values. Using these and the consensus defined 46 U, Kaplan-
Meier analyses demonstrated similarly significant higher risk of composite endpoint with
higher risk but smaller at risk population with the higher cut-off values (Fig 1 A, 1B and 1C;
Fig 2). Different time-distribution of end-points and separation patterns of the Kaplan Meier
were observed using these values. Using the lowest consensus cut-off value, we observed a late
(>60 days) occurring difference of event frequencies, whereas the higher cut-off values
appeared to be better predictors for the earlier events. These findings may draw the attention
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to the fact that the proposed cut-off values for platelet function tests are mainly based on stent
implanted ACS populations while in different clinical scenarios the predictive value and the
optimal cut-offs may differ.
Study limitations
We have to acknowledge some limitations of our registry. The most important limitations are
the single-centre design and consequent small sample size and the lack of blinding. It was left
to the discretion of the operator to perform platelet function testing and not all of the patients
were tested. Furthermore, although our inclusion criteria allowed the inclusion of ISR patients
also presenting with acute coronary syndrome all of the cases entered the registry were treated
during an elective intervention. This allows only to draw conclusions regarding patients with
elective DEB treatment.
Conclusion
In stable angina patients treated with DEB due to ISR, HPR is significantly associated with a
higher risk for recurrent ischemic events, mostly due to a higher risk for MI and revasculariza-
tion. Regarding procedural characteristics, DEB length was an independent predictor of worse
outcome. Further studies may investigate the safety and efficacy of treatment modification
regarding P2Y12-inhibitor therapy and the optimal duration of treatment in DEB patients
with HPR.
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